✦ LIBER ✦

Targeted therapies: Cetuximab plus chemotherapy in patients with advanced NSCLC

✍ Scribed by Rasul, Kakil Ibrahim; Kerr, David J.

Book ID: 127316339
Publisher: Nature Publishing Group
Year: 2009
Tongue: English
Weight: 170 KB
Volume: 6
Category: Article
ISSN: 1759-4774
DOI: 10.1038/nrclinonc.2009.108

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

42IN ADVANCED NSCLC: MAINTENANCE WITH TA

42IN ADVANCED NSCLC: MAINTENANCE WITH TARGETED THERAPIES

✍ Gridelli, C. 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 71 KB

Targeted therapies for patients with adv

Targeted therapies for patients with advanced colorectal cancer: focus on cetuximab

✍ E. Van Cutsem; R. Labianca; F. Cognetti; J. Tabernero 📂 Article 📅 2006 🏛 Springer-Verlag 🌐 English ⚖ 183 KB

IIIB.3 Targeted therapies and chemothera

IIIB.3 Targeted therapies and chemotherapy: new challenge for the treatment of advanced NSCLC elderly patients

✍ Gridelli, C. 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 44 KB

Pharmacogenetic Profiling for Cetuximab

Pharmacogenetic Profiling for Cetuximab Plus Irinotecan Therapy in Patients With Refractory Advanced Colorectal Cancer

✍ Graziano, F.; Ruzzo, A.; Loupakis, F.; Canestrari, E.; Santini, D.; Catalano, V. 📂 Article 📅 2008 🏛 American Society of Clinical Oncology 🌐 English ⚖ 127 KB

Biological targeted therapies in patient

Biological targeted therapies in patients with advanced enteropancreatic neuroendocrine carcinomas

✍ Nicola Fazio; Saverio Cinieri; Katia Lorizzo; Michela Squadroni; Laura Orlando; 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 294 KB

PCN44 TREATMENT COSTS OF GRADE 3/4 ADVER

PCN44 TREATMENT COSTS OF GRADE 3/4 ADVERSE EVENTS RELATED TO FIRST-LINE THERAPY WITH BEVACIZUMAB PLUS CHEMOTHERAPY VERSUS CETUXIMAB PLUS CISPLATIN/VINORELBINE FOR PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN SPAIN

✍ J de Castro Carpeño; K Banz; AJ Castro 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 81 KB